News - Cell Genesys Inc.
Cell Genesys, Inc. (Nasdaq:CEGE) today reported financial results for the third quarter ended September 30, 2008.
Cell Genesys, Inc. (Nasdaq:CEGE) today announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer.
Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the UBS Global Life Sciences Conference in New York City on Monday, September 22, 2008, at 11:30 a.m. ET.
Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the NewsMakers in the Biotech Industry Conference in New York City on Thursday, September 4, 2008, at 10:30 a.m. ET.